Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: October 2011
No. of Pages: 102
Price: $ 3500


Industry analysis specialist, GlobalData, has released its new report, “Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global type 1 diabetes therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global type 1 diabetes therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global type 1 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse All: Pharmaceuticals Market Research Reports

Scope
• The report provides information on the key drivers and challenges of the type 1 diabetes therapeutics market. Its scope includes:
• Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) type 1 diabetes therapeutics market revenue data for 2005–2010, and 2011–2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidate’s fall under the therapy classes such as immunomodulator, anti-CD3 antibody, oral Insulin analogue, GLP-1 receptor agonist, interleukin-1 inhibitor, ultra-long acting insulin analogue, ultra-fast-acting insulin analogue, Insulin analogue and ultra rapid-acting insulin analogue.
• Analysis of the current and future competition in the seven key countries of the type 1 diabetes therapeutics market. Biodel Inc., Eli Lilly and Company, Evotec, Diamyd Medical AB, Diasome Pharmaceutical Inc., Generex Biotechnology Corporation, GlaxoSmithKline, Halozyme Therapeutics Inc., MacroGenics, MannKind Corporation and Novo Nordisk, they are key market players, is covered in this section.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the type 1 diabetes therapeutics market.
• Analysis of key recent licensing and partnership agreements in type 1 diabetes therapeutics market.

Reasons to Buy
• The report will enhance your decision making capability. It will allow you to:
• Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes therapeutics market.
• Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global type 1 diabetes therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global type 1 diabetes therapeutics market landscape? – Identify, understand and capitalize.